Overall verdict
Neutral
6.1/10
1-year performance
+38.33%
Score breakdown
Up 38.3% over 1 year, 100% of the 52-week range.
Strongest: Profitability 8.8/10. Weakest: Financial strength 4.4/10.
17 analysts, target -0.0% vs the price.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.
In addition, the company offers risk assessment services for the life insurance industry ; healthcare IT healthcare providers and payers ; testing and medical director services at hospital laboratories ; test offerings in cardiometabolic and endocrine ; cancer ; clinical drug monitoring and toxicology ; infectious disease, including autoimmune ; neurology diagnostics, including Alzheimer's disease ;
and women's health, such as prenatal genetic ; workplace drug testing, testing urine, hair, and oral fluid specimens services ; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions ; extended care services ; develops in vitro diagnostic tests ; laboratory diagnostic information and digital health connectivity systems ;
underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics ; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
James Davis
Founded
1967
Employees
57 000
Revenue / employee
193 596 USD
Next earnings
February 5, 2027 (estimated)
Institutional holders
- FMR LLC4.10%
- GEODE CAPITAL MANAGEMENT, LLC2.88%
- Bank of New York Mellon Corp0.56%
- Rest of the register92.46%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
260.56 USD
52-week low
171.18 USD
1-year performance
38.33%
Rising
Year-to-date performance
50.34%
Rising
Drawdown
0.00%
Near its high
Position in the 52-week range
100% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 1.8 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| Quest Diagnostics | $100,861 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.8 times as much as the world ETF.
- Worst fall:-43 % between April 2002 and February 2003. $10,000 placed at the top fell to $5,742. The world ETF, at worst: -53 %. Back to its high in 21 months.
Quest Diagnostics earned more than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Quest Diagnostics: $100,861
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 235.00 USD - 236.82 USD (3 methods agree)
The price implies growth of 5.54% per year; the company grows at -3.64%.
Gross margin 31.9%, net margin 9.5%, ROIC 8.4%, ROE 15.1%.
Net margin
9.50%
Exceptional
Sector 4.51%|S&P 13.40%
Gross margin
31.91%
Fair
Return on equity (ROE)
15.11%
Exceptional
Sector 10.36%|S&P 17.06%
Return on invested capital (ROIC)
8.43%
Exceptional
Free cash flow margin (FCF)
11.61%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.22x
Fair
Margin stability
3.1 pts
Steady
Revenue to net income
Growth
5.2/10Revenue up 10.0% over 1 year, 3.2% a year over 5, EPS -3.6% a year over 5.
Revenue (trailing 12 months)
11.8Md USD
Revenue growth (1y)
9.98%
Solid
Revenue growth (3y)
11.66%
Moderate
EPS growth (1y)
28.72%
Solid
EPS CAGR (5y)
-3.64%
Declining
EPS revisions (3 months)
1.12%
Revised up
Valuation
5.3/10P/E 25.9x, forward P/E 25.2x, EV/EBITDA 14.5x, PEG 1.44. The multiple sits in the 100th percentile of its own 5-year history.
P/E (TTM)
25.9x
Fair
Sector 27.8x|S&P 23.6x
Forward P/E
25.2x
Fair
EV / EBITDA
14.5x
Fair
Sector 12.5x|S&P 15.5x
PEG
1.44
Fair
Sector 0.30|S&P 0.91
Fair value (reverse DCF)
235.91 USD
Fairly priced
P/E vs its own 5-year history
among the 1% highest valuations
At its historical high
Market cap
28.7Md USD
Financial strength
4.4/10Cash covers 12.7% of the debt, net debt/EBITDA 2.8x.
Net debt / EBITDA
2.8x
Tight
Gearing (net debt / equity)
68.34%
Tight
Cash
797M USD
Cash / market cap
2.78%
Stretched
Cash / total debt
12.68%
Stretched
Interest coverage
9.4x
Solid
Net debt
5.5Md USD
Equity
8.0Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 258.44 USD
- MM20246.08
- MM50240.07
- MM200214.56
- RSI 1468.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+3.31%
200-day average slope, 3 months
+9.44%
50-day average slope, 1 month
+1.10%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.37 % per day
Volatility change
-6.13%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 10.32 (9) | 11.32 (16) | 12 084 (15) | 2 380 (6) | 1 164 (7) |
| 2027 | 10.96 (9) | 11.98 (16) | 12 622 (15) | 2 660 (6) | 1 237 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 76 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DVA | 6.6 | 6.5 | 11.5Md USD | 13.9x | 6.3 % | 4.6 % | 7.5 % | 4.5x | 11.2 % | 52.1 % | ||
| 2 | CVS | 6.5 | 6.0 | 115Md USD | 10.4x | 2.6 % | 5.4 % | 7.4 % | 4.1x | 13.6 % | 14.8 % | ||
| 3 | HNGE | 6.4 | 7.0 | 9.5Md USD | 61.3x | 20.7 % | 52.4 % | 44.7 % | -1.6x | 3.3 % | 171.5 % | ||
| 4 | DGX | 6.1 | 6.1 | 28.7Md USD | 25.9x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 4.8 % | 38.3 % | ||
| 5 | CI | 6.1 | 6.1 | 79.4Md USD | 13.3x | 2.1 % | 5.7 % | 8.3 % | 1.8x | 10.4 % | 15.8 % | ||
| 6 | BTSG | 6.0 | 4.7 | 14.5Md USD | 47.2x | 2.0 % | 26.4 % | 7.0 % | 4.6x | 3.4 % | 116.3 % | ||
| 7 | FME | 5.4 | 5.4 | 12.0Md USD | 13.6x | 4.2 % | 1.1 % | 3.8 % | 2.7x | 17.0 % | -0.5 % | ||
| 8 | GH | 5.3 | 3.6 | 20.9Md USD | Not meaningful (loss) | -37.9 % | 36.1 % | -41.6 % | -1.4x | -1.1 % | 59.9 % | ||
| 9 | LH | 5.3 | 4.4 | 30.2Md USD | 30.5x | 6.9 % | 6.9 % | 6.8 % | 2.4x | 4.3 % | 41.7 % |
